Dexter Tjoa, CEO of Tjoapack explores the innovations set to transform secondary pharmaceutical packaging from 2024 onwards.   Enhancing the patient experience  Patient centricity is one of the major themes in both drug formulation development...

Renovos Biologics (Renovos) has announced the appointment of its new Non-Executive Director, Lisa Ferrara, Ph.D. Dr Ferrara, who has an extensive amount of experience in helping new orthopaedic devices obtain regulatory approval in the...

Biocomposites has announced that it has acquired the remaining shares in Laboratories SL S.A. and Synergie Ingénierie Médicale S.A.R.L. This allows the medical devices company to gain full control of the SYNICEM and Subiton...

Asamedic, a pioneer in emergency medical treatment of myocardial infarction, and Bormioli Pharma, a leader in pharmaceutical packaging solutions, have announced a partnership for the commercialisation of Coxor 300mg Acetylsalicylic acid, a ‘revolutionary life-saving medication’ designed...

MM Packaging has outlined its agenda for the CPHI 2024 show. The secondary packaging specialists will be on hand to discuss a variety of packaging solutions that can be utilised both domestically and internationally....

Molex, a parent to Phillips Medisize, has announced that, through its affiliate Molex Asia Holdings LTD., it has signed an agreement to purchase Vectura Group Limited from Vectura Fertin Pharma Inc., a subsidiary of Philip Morris...

After winning approval for its respiratory syncytial virus (RSV) vaccination, Moderna has acknowledged that it has been more difficult than expected to win market share from its two key rivals in this field. In...

A peer reviewed study published in Frontiers in Neuroscience by academics at Aberdeen and Durham Universities has shown that Ellorarxine, a novel drug compound developed by biotech spinout Nevrargenics, has shown a robust neuroprotective effect in...

Richter BioLogics GmbH & Co KG (Richter BioLogics), the microbial biologics affiliate of Gedeon Richter PLC , has opened a new cutting-edge biopharmaceutical cGMP facility. Located in Bovenau, the new facility was opened on the 13th of...

DevCo Partners Ltd has announced a capital raise resulting in 616 million EUR of total commitments for its long-term single asset investment vehicle for Medix Biochemica. The transaction, as part of which ca. 300 million...

Combining a scientifically formulated dietary supplement, a wellness companion app, and a saliva-based a biological age test by Chronomics, Bayer is taking a step in the emerging healthy-ageing space by offering consumers new tools...

NanoSyrinx, a synthetic biology company developing nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, has announced that it has closed a 10 million GBP (13 million USD) financing round.  The...

NanoSyrinx, a synthetic biology company developing nanosyringes as a novel platform for targeted intracellular delivery of biologic therapeutics, has announced that it has closed a 10 million GBP (13 million USD) financing round.  The...

Owen Mumford, a company in the design, manufacture, and advancement of medical devices, has renewed its long-standing logistics partnership with Davies Turner for an additional three-year term. The renewed contract, which emphasises a long-term commitment,...

BGS Beta-Gamma-Service, a specialist for more than 40 years in the use of beta and gamma rays for radiation sterilisation for medical devices, pharmaceutical packaging, and biotechnology products, will open its first facility in the...

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, has announced its selection to present a poster at the European Society of Medical Oncology (ESMO) Congress 2024, which will take...

Biocomposites announces its distribution of the NanoBone product range in the UK. The international medical devices company will supply the NanoBone SBX Putty and NanoBone QD products which provide synthetic bone grafts for reliable, early osteogenesis...

Arrowhead Pharmaceuticals has been granted breakthrough therapy designation from the US Food and Drug Administration (FDA) regarding its potential RNA interference (RNAi) therapeutic, plozasiran. The treatment is said to have shown “promising results” in trials...

Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), has announced a collaboration with 3P innovation, a leading engineering company and supplier of automated...